Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods Adverse event (AE) reports in the FAERS database from January 2021 to December 2023 were...
| 出版年: | Lupus Science and Medicine |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMJ Publishing Group
2025-01-01
|
| オンライン･アクセス: | https://lupus.bmj.com/content/12/1/e001400.full |